
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current BCAX market cap is 675.84M. The company's latest EPS is USD -0.9553 and P/E is -13.02.
Quarter End | Sep 2024 |
---|---|
USD (US$) | |
Total Revenue | 0 |
Operating Income | -20.63M |
Net Income | -17.48M |
Year End 31 December 2023 | 2023 |
---|---|
USD (US$) | |
Total Revenue | 0 |
Operating Income | -39.89M |
Net Income | -51.99M |
Quarter End | Sep 2024 |
---|---|
USD (US$) | |
Total Assets | 524.17M |
Total Liabilities | 14.62M |
Total Equity | 509.56M |
Year End 31 December 2023 | 2023 |
---|---|
USD (US$) | |
Total Assets | 233.98M |
Total Liabilities | 15.47M |
Total Equity | -148.77M |
Market Cap | 675.84M |
Price to Earnings Ratio | -13.02 |
Price to Sales Ratio | 0 |
Price to Cash Ratio | 2.94 |
Price to Book Ratio | 3.1 |
Dividend Yield | - |
Shares Outstanding | 54.42M |
Average Volume (1 week) | 1.03M |
Average Volume (1 Month) | 553.96k |
52 Week Change | -52.69% |
52 Week High | 27.95 |
52 Week Low | 11.10 |
Spread (Intraday) | 1.09 (8.49%) |
Company Name | Bicara Therapeutics Inc |
Address |
corporation trust center wilmington, delaware 19801 |
Website | https://www.bicara.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions